DBH
DBH (dopamine beta-hydroxylase, also known as DBM) is an oxidoreductase that catalyses the hydroxylation of dopamine to noradrenaline, also called norepinephrine. It is vital for regulating these neurotransmitters and belongs to the copper type II ascorbate-dependent monooxygenase family. Browse Assay Genie's current range of DBH research reagents below, or read on for the biology behind the target.
DBH catalyses the hydroxylation of dopamine to noradrenaline (norepinephrine), and is therefore central to the regulation of these two neurotransmitters. Noradrenaline functions both as a hormone and as the main neurotransmitter of the sympathetic nervous system, so the activity of this enzyme sits at a key point in catecholamine signalling. The protein is an oxidoreductase and belongs to the copper type II ascorbate-dependent monooxygenase family, classified under EC 1.14.17.1.
The DBH gene encodes a protein expressed in neurosecretory vesicles and in the chromaffin granules of the adrenal medulla. UniProt places it in the secretory vesicle lumen and secretory vesicle membrane, including the chromaffin granule lumen and membrane, and it is also found in the secreted fraction. The enzyme exists in both soluble and membrane-bound forms, depending on the absence or presence, respectively, of a signal peptide. HGNC places the gene in the dopamine beta-hydroxylase family. Mouse and rat both have a Dbh ortholog.
Mutations in the DBH gene cause dopamine beta-hydroxylase deficiency in human patients, which is characterised by deficits in autonomic and cardiovascular function, including hypotension and ptosis. Polymorphisms in the gene may also play a role in a variety of psychiatric disorders. The protein has previously been named dopamine beta-monooxygenase, and DBM is a former symbol for the gene.
DBH converts dopamine to noradrenaline, making it a defining enzyme for studying how these neurotransmitters are produced and regulated.
Noradrenaline is the main neurotransmitter of the sympathetic nervous system, so DBH is relevant to studies of sympathetic signalling.
Mutations in DBH cause dopamine beta-hydroxylase deficiency, with autonomic and cardiovascular deficits including hypotension and ptosis.
Polymorphisms in the DBH gene may play a role in a variety of psychiatric disorders, making it a candidate in neuropsychiatric research.
DBH catalyses the hydroxylation of dopamine to noradrenaline (norepinephrine), and is vital for regulating these neurotransmitters. Noradrenaline acts as both a hormone and the main neurotransmitter of the sympathetic nervous system. The enzyme sits in secretory vesicles, including chromaffin granules of the adrenal medulla.
DBH is also known as dopamine beta-monooxygenase, and DBM is a previous gene symbol. The enzyme exists in soluble and membrane-bound forms, depending on the absence or presence, respectively, of a signal peptide. Its EC number is 1.14.17.1.
Mutations in DBH cause dopamine beta-hydroxylase deficiency, marked by autonomic and cardiovascular deficits such as hypotension and ptosis. Polymorphisms may contribute to psychiatric disorders. Mouse and rat each carry a Dbh ortholog; check the datasheet of any product for its validated reactivity.
Other catecholamine pathway enzymes and neurotransmitter-related targets with products at Assay Genie.
Gene and protein annotations from HGNC, NCBI Gene and UniProt P09172; product specifications from Assay Genie datasheets.